Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

• Market Cap: ₹22.92B
• Dividend Yield: 0.28%
• Average Volume (3M): 104.36K
• Price to Earnings (P/E): 18.6
• Beta (1Y): 1.52
• Revenue Growth: 7.51%
• EPS Growth: 71.81%
• Country: IN
• Employees: 831
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.20
• Shares Outstanding: 105,788,970
• 10 Day Avg. Volume: 77,644
• 30 Day Avg. Volume: 104,358
• PEG Ratio: 1.37
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.56
• P/FCF Ratio: 42.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹239.00 ▲(65.11% Upside)
• Action: Reiterated Date: 01/07/26
• Date: Action: Reiterated 01/07/26

The score is driven primarily by solid financial fundamentals—especially a strong, low-leverage balance sheet and improving profitability—supported by a clear technical uptrend. Valuation is reasonable on earnings but offers limited support from a very low dividend yield.

Positive Factors

Strong balance sheet with low leverage

A high equity ratio and low debt provide durable financial flexibility to fund working capital, bid on export/tender contracts, and absorb cyclical pressure in generics without relying on costly borrowing. Improved ROE indicates efficient capital use that supports long-term investment capacity and resilience.

Improving profitability and margins

Sustained gross, EBIT and EBITDA margin improvement signals structural cost control and better product mix execution, which supports repeatable operating cash generation. Strong margins create room to invest in quality, R&D or tender pricing while preserving profitability under competitive pressure.

Diversified revenue streams (domestic, exports, contract manufacturing)

A multi-channel model—finished dosages, exports and contract manufacturing—reduces reliance on any single market or buyer and provides multiple growth levers. Export and contract-manufacturing scale supports volume stability and recurring institutional/tender business over the medium term.

Negative Factors

Mixed and variable free cash flow profile

Variable free cash flow constrains the firm's ability to consistently fund capex, working capital spikes, dividends or acquisitions without drawing on reserves. Improving and stabilizing FCF is necessary to convert improved accounting margins into durable financial flexibility and strategic optionality.

Inconsistent EBITDA performance

Inconsistent EBITDA creates earnings volatility that can complicate long-term planning and undermine reinvestment or tender pricing strategies. Durable growth depends on steady operational performance; variability raises execution risk when scaling exports or third-party manufacturing.

Exposure to intense generics pricing and competitive dynamics

Relying on generic formulations and tender/export channels exposes margins to structural pricing pressure and regulatory barriers. Without distinct scale advantages or differentiated products, sustained margin protection and pricing power are at risk in highly commoditized markets.

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

How the Company Makes Money

Bliss Gvs Pharma generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and APIs. The company has established a solid presence in both domestic and international markets, leveraging partnerships with distributors and healthcare providers to expand its reach. Key revenue streams include sales of generic drugs, specialty medications, and OTC products. Additionally, Bliss Gvs Pharma benefits from strategic alliances and collaborations with other pharmaceutical companies, which enhance its product offerings and market penetration. By investing in research and development, the company aims to introduce new products, thereby driving future growth and profitability.

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Strong balance sheet (high equity, low leverage, improving ROE) and improving profitability/margins support the score. The main offset is mixed cash flow performance and variable free cash flow growth, suggesting room to improve cash generation.

Income Statement

Bliss Gvs Pharma Limited has shown consistent revenue growth over the years, with a notable increase in gross and net profit margins in the latest year. The EBIT and EBITDA margins have improved, indicating efficient cost management and operational performance. While the revenue growth trajectory is positive, there could be improved consistency in EBITDA performance.

Balance Sheet

The company maintains a strong balance sheet with a high equity ratio and low debt-to-equity ratio, showcasing financial stability and low leverage. The return on equity has seen improvement, reflecting the company's ability to generate profits from shareholders' equity. The company's strong equity position is a key strength.

Cash Flow

The cash flow position has been mixed, with variability in free cash flow growth rates. The operating cash flow to net income ratio indicates a healthy cash conversion cycle, but the free cash flow to net income ratio suggests room for improvement. The company should focus on optimizing capital expenditures to enhance free cash flow.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.34B	8.10B	7.66B	7.47B	7.38B	5.69B
Gross Profit	3.79B	3.96B	2.49B	3.50B	3.47B	2.40B
EBITDA	2.02B	1.27B	1.49B	1.35B	762.37M	1.27B
Net Income	1.07B	842.99M	754.54M	708.59M	150.40M	684.91M
Balance Sheet
Total Assets	0.00	13.01B	12.14B	11.57B	11.09B	10.77B
Cash, Cash Equivalents and Short-Term Investments	1.41B	1.41B	1.41B	684.11M	1.35B	616.64M
Total Debt	0.00	881.04M	998.40M	1.02B	1.09B	1.22B
Total Liabilities	-10.92B	2.09B	2.11B	2.39B	2.62B	2.49B
Stockholders Equity	10.92B	10.50B	9.67B	8.84B	8.19B	8.08B
Cash Flow
Free Cash Flow	0.00	298.48M	1.24B	-594.86M	614.77M	548.45M
Operating Cash Flow	0.00	1.06B	1.52B	343.13M	1.35B	639.69M
Investing Cash Flow	0.00	-754.41M	-1.33B	-77.51M	-929.75M	-469.91M
Financing Cash Flow	0.00	-303.45M	-208.93M	-249.38M	-237.30M	-207.98M

Bliss Gvs Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 144.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 144.75 is below the 20-day moving average (MA) of 212.85, below the 50-day MA of 186.60, and below the 200-day MA of 161.63, indicating a bullish trend. The MACD of 9.62 indicates Positive momentum. The RSI at 58.61 is Neutral, neither overbought nor oversold. The STOCH value of 29.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	74 Outperform	₹22.92B	18.57	―	0.28%	7.51%	71.81%
WINDLAS	71 Outperform	₹16.03B	27.93	―	0.71%	19.34%	9.32%
JAGSNPHARM	67 Neutral	₹11.40B	28.83	―	1.24%	24.60%	153.56%
SYNCOMF	67 Neutral	₹11.36B	17.72	―	―	56.41%	90.24%
HESTERBIO	61 Neutral	₹12.81B	38.81	―	0.44%	-3.84%	86.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAJAJHCARE	51 Neutral	₹10.03B	20.91	―	0.24%	13.04%	―

Bliss Gvs Pharma Limited Corporate Events

Bliss GVS Pharma Adds New Step-Down Subsidiary in DR Congo to Deepen African Reach

Bliss GVS Pharma Limited has expanded its African presence through its Singapore-based wholly owned subsidiary, Bliss GVS International PTE Ltd, which has incorporated a new step-down wholly owned subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, in Kinshasa–Gombe, Democratic Republic of the Congo. The new entity, established with a modest initial share capital of USD 1,000, signals the company’s continued strategic push into emerging healthcare markets, potentially strengthening its distribution, local market access, and positioning within the regional pharmaceutical landscape, though detailed operational plans and financial implications have not yet been disclosed.